201 related articles for article (PubMed ID: 28197368)
1. Immunosuppressive CD14
Javeed N; Gustafson MP; Dutta SK; Lin Y; Bamlet WR; Oberg AL; Petersen GM; Chari ST; Dietz AB; Mukhopadhyay D
Oncoimmunology; 2017; 6(1):e1252013. PubMed ID: 28197368
[TBL] [Abstract][Full Text] [Related]
2. The CD14
Mengos AE; Gastineau DA; Gustafson MP
Front Immunol; 2019; 10():1147. PubMed ID: 31191529
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma.
Gustafson MP; Lin Y; Bleeker JS; Warad D; Tollefson MK; Crispen PL; Bulur PA; Harrington SM; Laborde RR; Gastineau DA; Leibovich BC; Cheville JC; Kwon ED; Dietz AB
Clin Cancer Res; 2015 Sep; 21(18):4224-33. PubMed ID: 25999436
[TBL] [Abstract][Full Text] [Related]
4. Immune independent crosstalk between lymphoma and myeloid suppressor CD14
Zhang ZJ; Bulur PA; Dogan A; Gastineau DA; Dietz AB; Lin Y
Oncoimmunology; 2015 Apr; 4(4):e996470. PubMed ID: 26137410
[TBL] [Abstract][Full Text] [Related]
5. Elevated frequencies of CD14
Xue G; Jiang M; Zhao R; Le A; Li J
Aging (Albany NY); 2021 Feb; 13(5):6236-6246. PubMed ID: 33640878
[TBL] [Abstract][Full Text] [Related]
6. Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses.
Laborde RR; Lin Y; Gustafson MP; Bulur PA; Dietz AB
Front Immunol; 2014; 5():147. PubMed ID: 24772111
[TBL] [Abstract][Full Text] [Related]
7. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.
Gustafson MP; Lin Y; New KC; Bulur PA; O'Neill BP; Gastineau DA; Dietz AB
Neuro Oncol; 2010 Jul; 12(7):631-44. PubMed ID: 20179016
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.
Lin Y; Gustafson MP; Bulur PA; Gastineau DA; Witzig TE; Dietz AB
Blood; 2011 Jan; 117(3):872-81. PubMed ID: 21063024
[TBL] [Abstract][Full Text] [Related]
9. Circulating CD14
Stenzel AE; Abrams SI; Joseph JM; Goode EL; Tario JD; Wallace PK; Kaur D; Adamson AK; Buas MF; Lugade AA; Laslavic A; Taylor SE; Orr B; Edwards RP; Elishaev E; Odunsi K; Mongiovi JM; Etter JL; Winham SJ; Kaufmann SH; Modugno F; Moysich KB
Am J Reprod Immunol; 2021 Mar; 85(3):e13343. PubMed ID: 32905653
[TBL] [Abstract][Full Text] [Related]
10. [The expression and association of CD14(+) HLA-DR(Low/-) myeloid-derived suppressor cell-like cells and interleukin-1β in ovarian cancer].
Wang HY; Zhao R; Ren H; Zou MJ; Zhang J; Zhang Y
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2663-2669. PubMed ID: 28910953
[No Abstract] [Full Text] [Related]
11. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.
Mougiakakos D; Jitschin R; von Bahr L; Poschke I; Gary R; Sundberg B; Gerbitz A; Ljungman P; Le Blanc K
Leukemia; 2013 Feb; 27(2):377-88. PubMed ID: 22828446
[TBL] [Abstract][Full Text] [Related]
12. Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patients.
Hingorani P; Maas ML; Gustafson MP; Dickman P; Adams RH; Watanabe M; Eshun F; Williams J; Seidel MJ; Dietz AB
J Immunother Cancer; 2015; 3():35. PubMed ID: 26286851
[TBL] [Abstract][Full Text] [Related]
13. IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma.
Xiu B; Lin Y; Grote DM; Ziesmer SC; Gustafson MP; Maas ML; Zhang Z; Dietz AB; Porrata LF; Novak AJ; Liang AB; Yang ZZ; Ansell SM
Blood Cancer J; 2015 Jul; 5(7):e328. PubMed ID: 26230952
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive monocytes (CD14
Lima DS; Lemes RPG; Matos DM
Med Oncol; 2018 Feb; 35(3):36. PubMed ID: 29429058
[TBL] [Abstract][Full Text] [Related]
15. CD14(+) HLA-DR low/(-) monocytes as indicator of disease aggressiveness in B-cell non-Hodgkin lymphoma.
Khalifa KA; Badawy HM; Radwan WM; Shehata MA; Bassuoni MA
Int J Lab Hematol; 2014 Dec; 36(6):650-5. PubMed ID: 24636145
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of the morphological, cytochemical, immunophenotypical, and functional characteristics of normal human peripheral blood lineage(-)/CD16(+)/HLA-DR(+)/CD14(-/lo) cells, CD14(+) monocytes, and CD16(-) dendritic cells.
Almeida J; Bueno C; Algueró MC; Sanchez ML; de Santiago M; Escribano L; Díaz-Agustín B; Vaquero JM; Laso FJ; San Miguel JF; Orfao A
Clin Immunol; 2001 Sep; 100(3):325-38. PubMed ID: 11513546
[TBL] [Abstract][Full Text] [Related]
17. Immune monitoring using the predictive power of immune profiles.
Gustafson MP; Lin Y; LaPlant B; Liwski CJ; Maas ML; League SC; Bauer PR; Abraham RS; Tollefson MK; Kwon ED; Gastineau DA; Dietz AB
J Immunother Cancer; 2013; 1():7. PubMed ID: 25512872
[TBL] [Abstract][Full Text] [Related]
18. Systemic T Cells Immunosuppression of Glioma Stem Cell-Derived Exosomes Is Mediated by Monocytic Myeloid-Derived Suppressor Cells.
Domenis R; Cesselli D; Toffoletto B; Bourkoula E; Caponnetto F; Manini I; Beltrami AP; Ius T; Skrap M; Di Loreto C; Gri G
PLoS One; 2017; 12(1):e0169932. PubMed ID: 28107450
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
[TBL] [Abstract][Full Text] [Related]
20. CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
Speigl L; Burow H; Bailur JK; Janssen N; Walter CB; Pawelec G; Shipp C
Breast Cancer Res Treat; 2018 Apr; 168(2):401-411. PubMed ID: 29230664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
